Product leaflet for Fresenius Kabi Compound α‑Ketoacid Tablets, detailing composition, dosage, indications, and safety information.
This leaflet provides comprehensive information on Fresenius Kabi’s Compound α‑Ketoacid Tablets, a multi‑component oral formulation used in conjunction with a low‑protein diet to manage metabolic disturbances in chronic kidney disease. It lists the active keto‑amino‑acid calcium salts, essential amino acids, and total nitrogen and calcium content per tablet.
The document outlines indications, recommended dosage (4‑8 tablets three times daily for a 70 kg adult), contraindications, precautions, drug interactions, pharmacology, and storage conditions. It also includes regulatory details such as approval number, manufacturing company, and packaging specifications. This manual is written in Chinese.
| α‑Ketoisocaproic acid calcium | 67 mg per tablet |
|---|---|
| α‑Ketoisoleucine calcium | 101 mg per tablet |
| α‑Keto‑phenylalanine calcium | 68 mg per tablet |
| α‑Keto‑valine calcium | 86 mg per tablet |
| α‑Hydroxy‑isoleucine calcium | 59 mg per tablet |
| L‑Lysine acetate | 105 mg per tablet |
| Total nitrogen | 36 mg per tablet |
| Total calcium | 1.25 mmol ≈ 50 mg per tablet |
| Tablet weight | 0.63 g |
| Packaging | 100 tablets per aluminum‑plastic blister pack |
The product should not be used in patients with hypercalcemia, amino‑acid metabolism disorders, or phenylketonuria because it contains phenylalanine.
Blood calcium levels should be regularly monitored, and care should be taken to avoid excessive calcium intake from other sources.
Store the tablets below 25 °C in a dry environment.